The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Open accessAbstract
Proliferation Control: The protein complex mTORC1, which contains the protein kinase known as mammalian target of rapamycin, is an important regulator of cell proliferation and cell size. Among many targets, mTORC1 phosphorylates the eukaryotic translation initiation factor eIF4E–binding proteins (4E-BPs), thus controlling translation of proteins that regulate proliferation. Dowling et al. (p. 1172 ) used mice lacking expression of the 4E-BPs to show that these proteins contribute to mTORC1's activation of cell proliferation, but are dispensable for the effects of mTORC1 on cell growth. The latter required another mTORC1 target—the ribosomal protein S6 kinase. mTORC1 inhibitors are being explored as potential anticancer agents, and the presence of 4E-BPs was necessary for mTORC1 inhibitors to reduce the number and size of colonies formed by transformed mouse cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343
Self-citationmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239
Self-citationActive-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“In fibroblasts, mTORC1 promotes cell size increase mainly through S6Ks while driving cell-cycle progression mainly through the 4E-BP/eIF4E axis (Dowling et al., 2010).”
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Self-citationRegulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Morita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842
Self-citationGlucose–TOR signalling reprograms the transcriptome and activates meristems
Xiong, Y., McCormack, M., Li, L., Hall, Q., Xiang, C., & Sheen, J. (2013) · Nature · doi:10.1038/nature12030 · Cited by 818
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Self-citationmTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Herranz, N., Gallage, S., Mellone, M., Wuestefeld, T., Klotz, S., Hanley, C. J., Raguz, S., Acosta, J. C., Innes, A. J., Banito, A., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3225 · Cited by 788
“Thismaybeexplainedbythewelldescribed antiproliferative effects caused by mTOR inhibition 30,31 .”
Self-citationmTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation
Zhang, Y., Swanda, R. V., Nie, L., Liu, X., Wang, C., Lee, H., Lei, G., Mao, C., Koppula, P., Cheng, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21841-w · Cited by 698
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
mTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552
“, serum or amino-acid depletion).(83) These results suggest that mTOR coordinates mitochondrial functions and proliferation, at least in part by modulating translation programs (Fig.”
BackgroundSelf-citationQuantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
Robitaille, A. M., Christen, S., Shimobayashi, M., Cornu, M., Fava, L. L., Moes, S., Prescianotto-Baschong, C., Sauer, U., Jenoe, P., & Hall, M. N. (2013) · Science · doi:10.1126/science.1228771 · Cited by 525
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 463
mTOR in aging, metabolism, and cancer
Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 449
Anczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 447
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Kim, L. C., Cook, R. S., & Chen, J. (2017) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 444
The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A., Yu, B., Prakash Somasekharan, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 414
(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393
Shuda, M., Kwun, H. J., Feng, H., Chang, Y., & Moore, P. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46323 · Cited by 374
mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1
Morita, M., Prudent, J., Basu, K., Goyon, V., Katsumura, S., Hulea, L., Pearl, D., Siddiqui, N., Strack, S., McGuirk, S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.013 · Cited by 373
Self-citationTranslational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
Oh, W. J., Wu, C. ‐., Kim, S. J., Facchinetti, V., Julien, L. ‐., Finlan, M., Roux, P. P., Su, B., & Jacinto, E. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.271 · Cited by 333
The Akt pathway in oncology therapy and beyond (Review)
Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 328
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirovic, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 324
Self-citationGerminal Center Selection and Affinity Maturation Require Dynamic Regulation of mTORC1 Kinase
Ersching, J., Efeyan, A., Mesin, L., Jacobsen, J. T., Pasqual, G., Grabiner, B. C., Dominguez-Sola, D., Sabatini, D. M., & Victora, G. D. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.005 · Cited by 308
Growing knowledge of the mTOR signaling network
Huang, K., & Fingar, D. C. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.09.011 · Cited by 305
Molecular mechanisms of viral oncogenesis in humans
Krump, N. A., & You, J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0064-6 · Cited by 295
Ribosome Profiling: Global Views of Translation
Ingolia, N. T., Hussmann, J. A., & Weissman, J. S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032698 · Cited by 286
Park, Y., Reyna-Neyra, A., Philippe, L., & Thoreen, C. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.042 · Cited by 278
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
“4E-BP1 is the substrate through which mTORC1 controls cell proliferation 23 , so the resistance of its phosphorylation to rapamycin likely contributes to the poor efficiency of rapamycin as an anti-hyperplastic agent.”
BackgroundArl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252
Tcherkezian, J., Cargnello, M., Romeo, Y., Huttlin, E. L., Lavoie, G., Gygi, S. P., & Roux, P. P. (2014) · Genes & Development · doi:10.1101/gad.231407.113 · Cited by 257
Mechanisms Modulating Skeletal Muscle Phenotype
Blaauw, B., Schiaffino, S., & Reggiani, C. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c130009 · Cited by 256
Keeton, E. K., McEachern, K., Dillman, K. S., Palakurthi, S., Cao, Y., Grondine, M. R., Kaur, S., Wang, S., Chen, Y., Wu, A., et al. (2014) · Blood · doi:10.1182/blood-2013-04-495366 · Cited by 254
Translational reprogramming in cellular stress response
Liu, B., & Qian, S. (2014) · WIREs RNA · doi:10.1002/wrna.1212 · Cited by 253
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
The Role of Target of Rapamycin Signaling Networks in Plant Growth and Metabolism
Xiong, Y., & Sheen, J. (2014) · Plant Physiology · doi:10.1104/pp.113.229948 · Cited by 252
Jaramillo, M., Gomez, M. A., Larsson, O., Shio, M. T., Topisirovic, I., Contreras, I., Luxenburg, R., Rosenfeld, A., Colina, R., McMaster, R. W., et al. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.03.008 · Cited by 171
“Inhibitors of mTORC1, including rapamycin, block cell proliferation (Dowling et al., 2010).”
BackgroundSelf-citationGenetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J., & Sahin, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015354 · Cited by 163
Regulation of TOR by small GTPases
Durán, R. V., & Hall, M. N. (2012) · The EMBO Reports · doi:10.1038/embor.2011.257 · Cited by 102
TSC1/TSC2 signaling in the CNS
Han, J. M., & Sahin, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.001 · Cited by 105
“When phosphorylated by mTORC1, 4E-BP1 dissociates from the eIF4E complex, initiating mRNA translation [37,38].”
BackgroundPTEN/Akt Signaling Controls Mitochondrial Respiratory Capacity through 4E-BP1
Goo, C. K., Lim, H. Y., Ho, Q. S., Too, H.-P., Clement, M.-V., & Wong, K. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045806 · Cited by 97
mTOR signalling pathway - A root cause for idiopathic autism?
Ganesan, H., Balasubramanian, V., Iyer, M., Venugopal, A., Subramaniam, M. D., Cho, S.-G., & Vellingiri, B. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.137 · Cited by 73
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Bartalucci, N., Guglielmelli, P., & Vannucchi, A. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.07.011 · Cited by 49
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“The data suggest that rapamycin impairs mTORC1 activity mainly by preventing the association and phosphorylation of substrates into the kinase complex [33, 34].”
BackgroundHeightening Energetic Stress Selectively Targets LKB1-Deficient Non–Small Cell Lung Cancers
Momcilovic, M., McMickle, R., Abt, E., Seki, A., Simko, S. A., Magyar, C., Stout, D. B., Fishbein, M. C., Walser, T. C., Dubinett, S. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0797 · Cited by 46
“Previous studies have shown that 4E-BP1 is a critical mediator of tumor cell proliferation and survival downstream of mTOR signaling in normal and cancer cells (21).”
Dulic, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_2 · Cited by 42
Region-specific cellular and molecular basis of liver regeneration after acute pericentral injury.
Wang, S., Wang, X., Shan, Y., Tan, Z., Su, Y., Cao, Y., Wang, S., Dong, J., Gu, J., & Wang, Y. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.01.013 · Cited by 40
Self-citationThe mTORC1/S6K/PDCD4/eIF4A Axis Determines Outcome of Mitotic Arrest
Moustafa-Kamal, M., Kucharski, T. J., El-Assaad, W., Abbas, Y. M., Gandin, V., Nagar, B., Pelletier, J., Topisirovic, I., & Teodoro, J. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108230 · Cited by 31
Self-citationYoon, S., Kim, J. H., Kim, S.-E., Kim, C., Tran, P.-T., Ann, J., Koh, Y., Jang, J., Kim, S., Moon, H.-S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01190 · Cited by 17
Dadehbeigi, N., & Dickson, A. J. (2015) · Biotechnology Journal · doi:10.1002/biot.201500075 · Cited by 16
Metabolic regulation by biomaterials in osteoblast
Kang, Z., Wu, B., Zhang, L., Liang, X., Guo, D., Yuan, S., & Xie, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1184463 · Cited by 15
“While 4E-BP1 primarily regulates proliferation in various mammalian cells, often in an independent manner (Dowling et al., 2010).”
BackgroundYoon, S., Kim, J. H., Koh, Y., Tran, P.-T., Ann, J., Yoon, I., Jang, J., Kim, W. K., Lee, S., Lee, J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.002 · Cited by 15
Papadopoli, D., Palia, R., Jovanovic, P., Tabariès, S., Ciccolini, E., Sabourin, V., Igelmann, S., McLaughlan, S., Zhan, L., Kim, H., et al. (2026) · eLife · doi:10.7554/elife.106587.3 · Cited by 1
Self-citation
Metadata
- Authors
- Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S. C., Thomas, G., & Sonenberg, N.
- Venue
- Science
- Published
- 2010-05-28
- Volume
- 328
- Issue
- 5982
- Pages
- 1172-1176
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086338749
- Cited by
- 726
- References
- 26
- FWCI
- 25.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.